Atherosclerotic Cardiovascular Disease Market Size is Set for Rapid Growth as Innovative Treatments and Rising Awareness Drive Demand by 2034

The Atherosclerotic Cardiovascular Disease market size is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Amgen Inc., Novo Nordisk A/S, NewAmsterdam Pharma, Merck Sharp & Dohme Corp., LIB Therapeutics LLC, Ionis Pharmaceuticals, Inc., CSL Behring, Resverlogix Corp, Ionis Pharmaceuticals, Novartis Pharmaceuticals, Janssen Research & Development, LLC, Bristol-Myers Squibb, Silence Therapeutics Plc

[Nevada, United States] - DelveInsight's "Atherosclerotic Cardiovascular Disease Market Insights, Epidemiology, and Market Forecast 2034." report offers a detailed examination of Atherosclerotic Cardiovascular Disease, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Atherosclerotic Cardiovascular Disease Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/report-store/atherosclerotic-cardiovascular-disease-ascvd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Key Findings from the Atherosclerotic Cardiovascular Disease Market Report:
The Atherosclerotic Cardiovascular Disease market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2020-2034).
In October, 2024: Novartis Pharmaceuticals announced that the CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants with established cardiovascular disease (CVD).
In October, 2024: Eli Lilly and Company announced that the purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke. The study drug will be administered subcutaneously (SC) (under the skin).
In October, 2024: Novo Nordisk A/S announced that their study is conducted to see if ziltivekimab reduces the risk of having cardiovascular events (for example heart attack and stroke) in people with cardiovascular disease, chronic kidney disease and inflammation.
In October, 2024: Lisata Therapeutics, Inc. a prospective, open label, controlled, randomized, double arm, multi-center study to assess the efficacy and safety of CLBS12 in patients with critical limb ischemia (CLI) due to arteriosclerosis obliterans (ASO) with a single arm sub-study to assess the safety and potential efficacy of CLBS12 in patients with CLI due to Buerger's Disease (BD).
In September, 2024: Beijing Northland Biotech. Co., Ltd. announced that their study will evaluate the safety and efficacy of recombinant human hepatocyte growth factor (HGF) bare plasmid injection for local intramuscular injection in the treatment of patients with severe lower limb hemorrhagic disease (Rutherford grade 4)
The total diagnosed prevalent cases of ASCVD in the 7MMwere 55,455,209 cases in2022and this number ispredicted to climb at a substantial CAGR throughout the study period (2020-2034).
The total diagnosed prevalent cases of ASCVD in the US accounted for highest cases among the 7MM with26,043,092 cases, which is expected to show a steep rise soon due to the improvement in diagnostic testingand increasing population.
Japan accounted for 8,228,510 diagnosed prevalent cases of ASCVD in 2022 which are anticipated to rise bythe end of 2034.
Key Atherosclerotic Cardiovascular Disease Companies are as follows: Amgen Inc., Novo Nordisk A/S, NewAmsterdam Pharma, Merck Sharp & Dohme Corp., LIB Therapeutics LLC, Ionis Pharmaceuticals, Inc., CSL Behring, Resverlogix Corp, Ionis Pharmaceuticals, Novartis Pharmaceuticals, Janssen Research & Development, LLC, Bristol-Myers Squibb, Silence Therapeutics Plc
Key Atherosclerotic Cardiovascular Disease Therapies are as follow: Aliskiren, Rivaroxaban, Dalcetrapib, Bempedoic, Ezetimibe, Rosuvastatin, Ezetimibe, Xenon, Sevoflurane, LY3473329, Adalimumab, BO-653, Vorapaxar, Aspirin, Ezetimibe, rosuvastatin, RVX000222
Launching multiple stage Atherosclerotic Cardiovascular Disease pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Dive into our detailed Atherosclerotic Cardiovascular Disease market research report to uncover actionable insights, industry forecasts, and competitive analysis @ https://www.delveinsight.com/sample-request/atherosclerotic-cardiovascular-disease-ascvd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Atherosclerotic Cardiovascular Disease Overview:
Atherosclerotic Cardiovascular Disease (ASCVD) is a medical condition that causes arteries to narrow,restricting healthy blood flow to organs and the arms and legs due to plaque accumulation. This leads toheart attacks and strokes as the blood flow to the heart or brain gets blocked.

Atherosclerotic Cardiovascular Disease Epidemiology Segmentation:
The Atherosclerotic Cardiovascular Disease market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
Atherosclerotic Cardiovascular Disease Total Diagnosed Prevalent Cases
Atherosclerotic Cardiovascular Disease Gender-specific Diagnosed Prevalent Case
Atherosclerotic Cardiovascular Disease Age-specific Diagnosed Prevalent Cases
Atherosclerotic Cardiovascular Disease Comorbidity-specific Diagnosed Prevalent Cases

For more information about Atherosclerotic Cardiovascular Disease companies working in the treatment market, visit https://www.delveinsight.com/sample-request/atherosclerotic-cardiovascular-disease-ascvd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Atherosclerotic Cardiovascular Disease Market Insights
The treatment of ASCVD aims to mitigate the risk of cardiovascular events by addressing underlying causes suchas high cholesterol, hypertension, and diabetes through lifestyle modifications, medications, and interventions,thereby improving blood vessel health, relieving symptoms, and enhancing overall cardiovascular well-being. Theapproach to treatment can differ based on factors such as the disease's severity, the individual patient'scharacteristics, and their risk profile.

Atherosclerotic Cardiovascular Disease Drugs Uptake
Atorvastatin (Lipitor) and rosuvastatin (Crestor) are widely prescribed and have proven efficacy in lowering LDL-C levels and reducing the risk of cardiovascular events. Statins are typically the first-line therapy for most patients with high cholesterol or a history of ASCVD.
Alirocumab (Praluent) and evolocumab (Repatha) are the leading PCSK9 inhibitors. These drugs are especially useful for patients who are statin-intolerant or who do not achieve adequate cholesterol control with statins alone. Clinical trials have shown that PCSK9 inhibitors can reduce cardiovascular events by 15-20%.
The IMPROVE-IT trial demonstrated the benefits of combining ezetimibe with statins, showing a modest but significant reduction in cardiovascular events.
Bempedoic acid (Nexletol) is an oral, first-in-class ATP-citrate lyase inhibitor used to lower LDL-C. Approved by the FDA in 2020, it is an option for patients who need additional cholesterol reduction beyond statins or PCSK9 inhibitors.

Dive into our comprehensive market research report to discover in-depth insights, emerging trends, and strategic opportunities @ https://www.delveinsight.com/sample-request/atherosclerotic-cardiovascular-disease-ascvd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Atherosclerotic Cardiovascular Disease Therapies and Key Companies:
Aliskiren: Novartis
Rivaroxaban: Asan Medical
Dalcetrapib: Hoffmann-La Roche
Bempedoic, Ezetimibe: Esperion Therapeutics, Inc.
Rosuvastatin, Ezetimibe: AstraZeneca
Xenon, Sevoflurane: Air Liquide Santé International
LY3473329: Eli Lilly and Company
Adalimumab: Innovaderm Research Inc.
BO-653: Chugai Pharma USA
Vorapaxar, Aspirin: Merck Sharp & Dohme LLC
Ezetimibe: Organon and Co
rosuvastatin: Yuhan Corporation
RVX000222: Resverlogix Corp

Atherosclerotic Cardiovascular Disease Epidemiology:
ASCVD is one of the most prevalent cardiovascular diseases worldwide, affecting millions of people. It encompasses a wide range of conditions, including coronary artery disease (CAD), cerebrovascular disease (stroke), and peripheral artery disease (PAD). The global prevalence of ASCVD is alarmingly high. According to the World Health Organization (WHO), cardiovascular diseases account for an estimated 17.9 million deaths each year, with ASCVD being the leading cause. Coronary artery disease, the most common form of ASCVD, affects over 126 million individuals globally, accounting for approximately 1.72% of the world's population.

Seize Market Opportunities with Our Expert Analysis! Our report delivers valuable insights into market dynamics, key players, and emerging trends @ https://www.delveinsight.com/sample-request/atherosclerotic-cardiovascular-disease-ascvd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Atherosclerotic Cardiovascular Disease Market Drivers:
Increasing Disease Burden
Advances in Drug Development
Emphasis on Preventive Care
Favorable Reimbursement Policies

Atherosclerotic Cardiovascular Disease Market Barriers:
High Cost of Innovative Therapies
Limited Access in Low- and Middle-Income Countries
Competition from Generic Drugs

Stay Ahead in a Competitive Landscape with Our Exhaustive Market Research Report-Dive Into Detailed Analysis, Key Trends, and Future Projections @ https://www.delveinsight.com/sample-request/atherosclerotic-cardiovascular-disease-ascvd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Scope of the Atherosclerotic Cardiovascular Disease Market Report:
Study Period: 2020-2034
Coverage: 7MM (The United States, EU5, and Japan)
Key Atherosclerotic Cardiovascular Disease Companies: Amgen Inc., Novo Nordisk A/S, NewAmsterdam Pharma, Merck Sharp & Dohme Corp., LIB Therapeutics LLC, Ionis Pharmaceuticals, Inc., CSL Behring, Resverlogix Corp, Ionis Pharmaceuticals, Novartis Pharmaceuticals, Janssen Research & Development, LLC, Bristol-Myers Squibb, Silence Therapeutics Plc.
Key Atherosclerotic Cardiovascular Disease Therapies: Aliskiren, Rivaroxaban, Dalcetrapib, Bempedoic, Ezetimibe, Rosuvastatin, Ezetimibe, Xenon, Sevoflurane, LY3473329, Adalimumab, BO-653, Vorapaxar, Aspirin, Ezetimibe, rosuvastatin, RVX000222
Atherosclerotic Cardiovascular Disease Therapeutic Assessment: Current marketed and emerging therapies
Atherosclerotic Cardiovascular Disease Market Dynamics: Atherosclerotic Cardiovascular Disease Market drivers and Atherosclerotic Cardiovascular Disease barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Atherosclerotic Cardiovascular Disease Unmet Needs: Insights into unmet needs, KOL's views, Analyst's views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Atherosclerotic Cardiovascular Disease market outlook, drug uptake, treatment scenario, and epidemiology trends, https://www.delveinsight.com/sample-request/atherosclerotic-cardiovascular-disease-ascvd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Table of Content:

1. Key Insights
2. Report Introduction
3. Atherosclerotic Cardiovascular Disease (ASCVD) Market Overview by Therapies
4. Methodology of ASCVD Epidemiology and Market
5. Executive Summary of Atherosclerotic Cardiovascular Disease (ASCVD)
6. Key Events
7. Disease Background and Overview: ASCVD
8. Epidemiology and Patient Population
9. Patient Journey
10. Atherosclerotic Cardiovascular Disease Marketed Drugs
11. Atherosclerotic Cardiovascular Disease Emerging Drugs
12. ASCVD: Market Analysis
13. Key Opinion Leaders' Views
14. SWOT Analysis
15. Unmet Needs
16. Market Access and Reimbursement
17. Appendix
18. Report Methodology
19. DelveInsight Capabilities
20. Disclaimer

About DelveInsight:
DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Contact Information:
Company Name: DelveInsight Business Research LLP
Contact Person: Ram Kapoor
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

This release was published on openPR.